Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience.
definitive radiotherapy
local failure
oral cancer
systemic therapy
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
19 11 2021
19 11 2021
Historique:
received:
13
05
2021
accepted:
21
09
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
3
2
2022
Statut:
epublish
Résumé
Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC. We retrospectively examined 49 patients with non-metastatic primary unresectable OCC treated with definitive RT between 2000 and 2019. The majority of patients (63.3%) were treated with definitive chemoradiotherapy while 26.5% were given single-agent cetuximab weekly simultaneous to definitive RT. Five patients were treated with definitive RT alone because of limited disease and no nodal involvement. Median follow-up was 73 months (range, 6-236 months), median progression free survival (PFS) was 42 months (range, 2-157 months), median local disease-free survival (LDFS) was 44 months (range, 2-157 months) and median overall survival (OS) from the time of RT initiation was 52 months (range, 5-236 months). There were 65.3% locoregional failures, 84.4% local and 15.6% distant metastasis. The majority of patients with local failure presented with American Joint Committee on Cancer (AJCC) Stage III-IV disease (59.2%). The 5-year Kaplan-Meier estimates for OS (III-IV Definitive RT with or without concurrent systemic agents in patients with unresectable OCC resulted in an eloquent rate of locoregional control and good overall survival rates and is currently the best available treatment option in this patient collective.
Sections du résumé
BACKGROUND
Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC.
PATIENTS AND METHODS
We retrospectively examined 49 patients with non-metastatic primary unresectable OCC treated with definitive RT between 2000 and 2019. The majority of patients (63.3%) were treated with definitive chemoradiotherapy while 26.5% were given single-agent cetuximab weekly simultaneous to definitive RT. Five patients were treated with definitive RT alone because of limited disease and no nodal involvement.
RESULTS
Median follow-up was 73 months (range, 6-236 months), median progression free survival (PFS) was 42 months (range, 2-157 months), median local disease-free survival (LDFS) was 44 months (range, 2-157 months) and median overall survival (OS) from the time of RT initiation was 52 months (range, 5-236 months). There were 65.3% locoregional failures, 84.4% local and 15.6% distant metastasis. The majority of patients with local failure presented with American Joint Committee on Cancer (AJCC) Stage III-IV disease (59.2%). The 5-year Kaplan-Meier estimates for OS (III-IV
CONCLUSIONS
Definitive RT with or without concurrent systemic agents in patients with unresectable OCC resulted in an eloquent rate of locoregional control and good overall survival rates and is currently the best available treatment option in this patient collective.
Identifiants
pubmed: 34821134
pii: raon-2021-0041
doi: 10.2478/raon-2021-0041
pmc: PMC8647789
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-473Informations de copyright
© 2021 Kristin Lang, Melissa Baur, Thomas Held, Rami El Shafie, Julius Moratin, Christian Freudlsperger, Karim Zaoui, Nina Bougatf, Jürgen Hoffmann, Peter K. Plinkert, Jürgen Debus, Sebastian Adeberg, published by Sciendo.
Références
Int J Oral Maxillofac Surg. 2003 Jun;32(3):289-95
pubmed: 12767877
Radiat Oncol. 2012 Jun 11;7:84
pubmed: 22686297
Radiother Oncol. 2011 Jul;100(1):33-40
pubmed: 21684027
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1011-9
pubmed: 20434273
Oral Oncol. 2009 Apr-May;45(4-5):301-8
pubmed: 19249237
Oral Oncol. 2009 Apr-May;45(4-5):394-401
pubmed: 18674952
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Clin Oncol. 2021 Jan 1;39(1):38-47
pubmed: 33052757
Am J Clin Oncol. 2011 Aug;34(4):356-61
pubmed: 21633289
J Clin Oncol. 2007 Sep 10;25(26):4118-26
pubmed: 17827462
Oral Oncol. 2015 Jul;51(7):709-15
pubmed: 25958830
J Otolaryngol Head Neck Surg. 2015 May 13;44:17
pubmed: 25964113
Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):17-21
pubmed: 8416876
Cancer. 2015 May 15;121(10):1599-607
pubmed: 25639864
Lancet. 2000 Mar 18;355(9208):949-55
pubmed: 10768432
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Nat Clin Pract Oncol. 2005 Jan;2(1):34-9
pubmed: 16264854
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Lancet Oncol. 2010 Jan;11(1):66-74
pubmed: 19875337
Radiother Oncol. 2021 Jan;154:70-75
pubmed: 32861702
Med Oral Patol Oral Cir Bucal. 2013 Mar 01;18(2):e233-40
pubmed: 23385513
Comput Methods Programs Biomed. 2014 Apr;114(2):206-17
pubmed: 24629596
Oral Oncol. 2018 May;80:16-22
pubmed: 29706184
Int J Oral Maxillofac Surg. 2003 Feb;32(1):30-4
pubmed: 12653229
Laryngoscope. 2010 Jan;120(1):93-9
pubmed: 19856305
J Cancer Res Ther. 2010 Jul-Sep;6(3):282-9
pubmed: 21119254
Strahlenther Onkol. 2019 Sep;195(9):819-829
pubmed: 31267170
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688